The gold standard in GLP-1 weight management
A GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Educational content. This page describes Semaglutide for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
The landmark SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with overweight/obesity.[8]
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes and subsequently approved for chronic weight management. It is a synthetic analog of the naturally occurring GLP-1 hormone, engineered with structural modifications that extend its half-life to approximately one week, allowing once-weekly dosing. It is marketed as Wegovy (for obesity) and Ozempic (for diabetes).
Semaglutide received FDA approval for chronic weight management in June 2021 based on the STEP clinical trial program, which enrolled over 4,500 participants across four phase 3 trials. It has become the most widely prescribed GLP-1 receptor agonist for weight loss, representing a paradigm shift in obesity pharmacotherapy.
Semaglutide mimics the incretin hormone GLP-1, naturally released from the gut after eating. It binds to GLP-1 receptors in the pancreas, gut, and brain, triggering metabolic effects. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release.
In the brain, semaglutide acts on hypothalamic appetite centers to reduce hunger and increase satiety. It slows gastric emptying, meaning food stays in the stomach longer, contributing to reduced food intake and smaller meal sizes.
The cardiovascular benefits extend beyond weight loss. Semaglutide reduces systemic inflammation, improves endothelial function, and favorably modifies lipid profiles. The SELECT trial demonstrated meaningful reductions in heart attack, stroke, and cardiovascular death.
The gold standard in GLP-1 weight management
Semaglutide binds to GLP-1 receptors throughout the body, activating cAMP signaling in pancreatic beta cells to enhance insulin secretion, acting on hypothalamic neurons to suppress appetite, slowing gastric emptying to prolong satiety, and reducing systemic inflammation — collectively driving weight loss and cardiometabolic improvement.
Key studies supporting the therapeutic use of this peptide.
Mean 14.9% weight loss vs 2.4% placebo at 68 weeks. 86.4% achieved >=5% loss.
Wilding JPH, Batterham RL, Calanna S, et al. — N Engl J Med, 384(11):989-1002 (2021) · PubMed
16.0% weight loss vs 5.7% placebo at 68 weeks when combined with intensive behavioral therapy.
Wadden TA, Bailey TS, Billings LK, et al. — JAMA, 325(14):1403-1413 (2021) · PubMed
Continued semaglutide maintained -17.4% total loss at 68 weeks vs regain in placebo group.
Rubino D, Abrahamsson N, Davies M, et al. — JAMA, 325(14):1414-1425 (2021) · PubMed
20% reduction in major adverse cardiovascular events (HR 0.80) over mean 39.8 months.
Irfan H — Curr Probl Cardiol, 49(1 Pt A):102060 (2024) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection (Wegovy)
Oral (Rybelsus)
Subcutaneous Injection (Wegovy): 16-week escalation: 0.25→0.5→1.0→1.7→2.4 mg
Oral (Rybelsus): Take on empty stomach with <=4 oz water, 30 min before food
Dose escalation is critical to minimize gastrointestinal side effects. Do not skip the titration schedule.
If a dose is missed, administer within 5 days; if more than 5 days, skip and resume on schedule.
Injection sites should be rotated among abdomen, thigh, and upper arm.
Semaglutide has been extensively studied in over 16,000 participants. The most common adverse events are GI in nature and tend to diminish with gradual dose escalation.
A boxed warning exists for thyroid C-cell tumors based on rodent studies. Contraindicated in patients with MTC or MEN2 history.
Should be used with caution in patients with history of pancreatitis or severe GI disease. Discontinue at least 2 months before planned pregnancy.
See how Semaglutide compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Semaglutide | Weight Loss | Injection (weekly), Oral (daily) | Ongoing | Most clinically validated weight-loss peptide with cardiovascular outcomes data from the SELECT trial |
| Tirzepatide | Weight Loss | Injection (weekly) | Ongoing | Only dual GIP/GLP-1 agonist, producing up to 22.5% weight loss — the highest of any pharmacotherapy |
| Tesamorelin | Body Composition & GHRH | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog with Phase III data in over 800 patients, proven hepatoprotective effects, and physiologic pulsatile GH release |
| Ipamorelin | Anti-Aging & Body Composition | Injection (1-3x daily) | 8–12 weeks | Most selective GH secretagogue — clean pulsatile GH release without cortisol, prolactin, or appetite effects |
| AOD-9604 | Fat Reduction | Injection (daily) | 12-week cycles | GH's fat-burning effects without diabetogenic, anabolic, or IGF-1-elevating properties — though human trial efficacy was not demonstrated |
Current FDA classification and compounding eligibility.
This peptide is an FDA-approved drug available via standard prescription.
Multiple FDA approvals: Ozempic (2017, diabetes), Rybelsus (2019, oral diabetes), Wegovy (2021, weight loss), Wegovy HD (2025, higher dose). On April 30, 2026 the FDA proposed removing semaglutide from the 503B bulks list and tightened documentation requirements for 503A compounding. Public comment runs through June 29, 2026.
FDA proposed excluding semaglutide from the 503B bulks list and clarified 503A documentation standards
FDA approved Wegovy HD (semaglutide 7.2 mg) for weight loss and maintenance
FDA approved Wegovy (semaglutide 2.4 mg injection) for chronic weight management
FDA approved Rybelsus (oral semaglutide) for type 2 diabetes
FDA approved Ozempic (semaglutide injection) for type 2 diabetes
Last verified April 30, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Semaglutide? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA dual GIP and GLP-1 receptor agonist developed for diabetes and weight management.
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A selective ghrelin receptor agonist that prompts GH release without cortisol or prolactin effects.
Studied for body composition and recovery; ineligible for 503A compounding following the FDA PCAC safety review.